Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share
Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share On Wednesday, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) confirmed that, since March 2024, it ...